Nature Communications (Dec 2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- Chris T. Williamson,
- Rowan Miller,
- Helen N. Pemberton,
- Samuel E. Jones,
- James Campbell,
- Asha Konde,
- Nicholas Badham,
- Rumana Rafiq,
- Rachel Brough,
- Aditi Gulati,
- Colm J. Ryan,
- Jeff Francis,
- Peter B. Vermulen,
- Andrew R. Reynolds,
- Philip M. Reaper,
- John R. Pollard,
- Alan Ashworth,
- Christopher J. Lord
Affiliations
- Chris T. Williamson
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Rowan Miller
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Helen N. Pemberton
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Samuel E. Jones
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- James Campbell
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Asha Konde
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Nicholas Badham
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Rumana Rafiq
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Rachel Brough
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Aditi Gulati
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Colm J. Ryan
- Systems Biology Ireland, University College Dublin
- Jeff Francis
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Peter B. Vermulen
- The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research
- Andrew R. Reynolds
- The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research
- Philip M. Reaper
- Vertex Pharmaceuticals (Europe) Limited, Milton Park
- John R. Pollard
- Vertex Pharmaceuticals (Europe) Limited, Milton Park
- Alan Ashworth
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- Christopher J. Lord
- The CRUK Gene Function Laboratory, The Institute of Cancer Research
- DOI
- https://doi.org/10.1038/ncomms13837
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.
